All In Biotech

Drug Trial Radar · NCT04427930

Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial

Long-Term Safety and Efficacy Extension Study Of Autologous Adipose-Derived Mesenchymal Stem Cells 『JOINTSTEM』 in Patients With Knee Osteoarthiritis: A Phase III Extension Study

Last checked: Nov 19, 2026Latest source record: Jul 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

129

Actual

Start

Apr 13, 2020

Primary completion

Dec 23, 2026

Study completion Dec 30, 2027

Sponsor

Lead sponsor
R-BioIndustry
Sponsor type
Industry
First posted
Jun 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this follow-up study is to investigate the efficacy and safety of autologous Adipose Tissue derived Mesenchymal stem cells (JOINTSTEM®) in patient with severe Knee Osteoarthritis.

Conditions

  • Knee Osteoarthritis

Interventions

  • JOINTSTEMBiological

    Autologous Adipose Tissue derived MSCs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 5 Years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Keimyung University Dongsan Medical Center

    Daegu, South Korea

  • KyungHee University Gangdong Hospital

    Seoul, South Korea

  • Gangnam Severance Hospital

    Seoul, South Korea

  • The Catholic University of Korea, Seoul ST. Mary's Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.